#USA #Chicago #FDA Clearance #AIRS Medical #SwiftSight

AIRS Medical Launches SwiftSight® Body Composition with FDA Approval

AIRS Medical has recently made headlines by announcing the receipt of 510(k) clearance from the U.S. Food and Drug Administration for its innovative SwiftSight® Body Composition solution. This groundbreaking development signifies a major advancement in quantitative magnetic resonance imaging (MRI) technology, as it allows imaging organizations to perform comprehensive body composition analysis with speed and precision.

The SwiftSight® Advantage

SwiftSight® Body Composition takes advantage of AI-powered MRI analysis to deliver detailed quantitative assessments of muscle and fat distribution from MR images. This includes evaluations of visceral and subcutaneous fat, muscle quality, and bilateral muscle balance. The system is designed to analyze an individual’s body composition in under five minutes, followed by automated AI-driven analysis, making it suitable for implementation in high-volume medical imaging centers.

Jina Park, Chief Strategy Officer at AIRS Medical, emphasizes the importance of quick and practical assessments: "Tracking body composition changes over time is crucial for preventive health and weight management. That’s why we created SwiftSight Body Composition with a scan duration of less than five minutes. We want individuals actively engaged in their health to have reliable, quantitative measurements at their disposal."

Revolutionizing MRI Workflows

With an automated scan-to-report workflow, SwiftSight® Body Composition seamlessly integrates into existing MRI operations without the need for new imaging modalities or cumbersome manual analysis processes. This capability not only simplifies operations but also enhances consistency in patient experiences across different locations. Imaging networks can now provide standardized quantitative body composition analysis regardless of where a patient is scanned, reinforcing continuity of care over time.

Ajit Shankaranarayanan, PhD, Chief Product Officer at AIRS Medical, shares a vision for the future of MRI: "The evolution of MRI technology is moving towards not just obtaining better images but ensuring standardized, quantitative data that can be uniformly utilized across imaging organizations. SwiftSight® Body Composition embodies this vision by automating the analysis of muscle and fat, simplifying the integration of advanced assessments into regular MRI practices."

More Than Just Weight and BMI

Traditionally, metrics like weight and Body Mass Index (BMI) fail to reflect the nuanced distribution of fat and muscle within the body. SwiftSight® offers healthcare professionals valuable insights by quantifying not only fat percentages but also detailed information about muscle quality, balance, and liver fat levels through precise measurements. The solution evaluates key muscle groups, including the abdominal muscles and thigh regions, while providing visual mappings for a thorough understanding of body composition.

Expanding Healthcare Opportunities

For imaging organizations, the launch of SwiftSight® Body Composition opens new pathways to enhance existing MRI services. By introducing advanced quantitative body composition assessments, organizations can effectively support whole-body imaging, preventive healthcare, and wellness initiatives, generating additional revenue from their MRI infrastructure.

Given that MRI does not use ionizing radiation, healthcare providers can utilize SwiftSight® for regular assessments, allowing comprehensive longitudinal tracking of body composition changes over time. This unique feature positions SwiftSight® as a vital tool in the fields of preventive health and active wellness.

Conclusion: A Future of Expanded Capabilities

With the FDA clearance of SwiftSight® Body Composition, AIRS Medical continues its commitment to empowering medical professionals with advanced MRI solutions. The approval further extends their range of quantitative analysis offerings, moving beyond brain imaging to offer broader applications in various areas of health assessment. The company plans to release even more capabilities in the future, such as diffusion tensor imaging (DTI) and quantitative joint applications, setting the stage for a more comprehensive MRI intelligence platform. For organizations looking to enhance their imaging performance, AIRS Medical's innovations pave the way for the future of MRI technology, emphasizing consistency, intelligence, and expanded functionality within existing frameworks.

For more information about AIRS Medical and SwiftSight®, visit airsmed.com.